Atara Biotherapeutics Inc (ATRA)
0.69
-0.01
(-1.40%)
USD |
NASDAQ |
Apr 26, 16:00
0.6911
0.00 (0.00%)
After-Hours: 20:00
Atara Biotherapeutics Enterprise Value: 30.63M for April 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 26, 2024 | 30.63M |
| April 25, 2024 | 31.80M |
| April 24, 2024 | 33.58M |
| April 23, 2024 | 34.05M |
| April 22, 2024 | 31.52M |
| April 19, 2024 | 27.17M |
| April 18, 2024 | 30.84M |
| April 17, 2024 | 33.60M |
| April 16, 2024 | 29.63M |
| April 15, 2024 | 29.27M |
| April 12, 2024 | 32.78M |
| April 11, 2024 | 33.35M |
| April 10, 2024 | 33.94M |
| April 09, 2024 | 37.71M |
| April 08, 2024 | 38.51M |
| April 05, 2024 | 40.67M |
| April 04, 2024 | 41.24M |
| April 03, 2024 | 34.21M |
| April 02, 2024 | 35.13M |
| April 01, 2024 | 34.81M |
| March 28, 2024 | 31.11M |
| March 27, 2024 | 31.83M |
| March 26, 2024 | 27.17M |
| March 25, 2024 | 28.23M |
| March 22, 2024 | 31.52M |
| Date | Value |
|---|---|
| March 21, 2024 | 28.13M |
| March 20, 2024 | 34.21M |
| March 19, 2024 | 20.96M |
| March 18, 2024 | 11.67M |
| March 15, 2024 | 14.36M |
| March 14, 2024 | 15.34M |
| March 13, 2024 | 19.28M |
| March 12, 2024 | 22.79M |
| March 11, 2024 | 25.50M |
| March 08, 2024 | 29.33M |
| March 07, 2024 | 22.39M |
| March 06, 2024 | 22.56M |
| March 05, 2024 | 21.88M |
| March 04, 2024 | 28.17M |
| March 01, 2024 | 30.31M |
| February 29, 2024 | 31.09M |
| February 28, 2024 | 29.23M |
| February 27, 2024 | 32.90M |
| February 26, 2024 | 23.96M |
| February 23, 2024 | 26.65M |
| February 22, 2024 | 32.06M |
| February 21, 2024 | 33.07M |
| February 20, 2024 | 37.73M |
| February 16, 2024 | 30.30M |
| February 15, 2024 | 30.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-78.99M
Minimum
Nov 10 2023
1.716B
Maximum
Dec 07 2020
482.70M
Average
482.96M
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.329M |
| Palatin Technologies Inc | 19.88M |
| iBio Inc | 16.00M |
| Theriva Biologics Inc | -13.02M |
| Oragenics Inc | 3.037M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -60.45M |
| Revenue (Quarterly) | 4.252M |
| Total Expenses (Quarterly) | 64.21M |
| EPS Diluted (Quarterly) | -0.56 |
| Gross Profit Margin (Quarterly) | 25.68% |
| Profit Margin (Quarterly) | -1.42K% |
| Earnings Yield | -379.7% |
| Normalized Earnings Yield | -379.71 |